Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 4

Effect of mch1N11 and anti-PD-1 therapy on establishing an immune-mediated resistance to E0771 rechallenge and presence of functional T cells. a Animals that received mch1N11 + anti-PD-1 treatment and underwent a complete tumor regression (Fig. 4) were rechallenged, along with naïve C57BL/6 mice, with E0771 cells (1.0 × 106). Cells were inoculated in the opposing mammary fat pad (4/5) from the previous initial inoculation (8/9). The presence of palpable tumors and growth kinetics was determined for each group. b EliSpot analysis of IFNγ in splenocytes cultured with and without irradiated E0771 cells. Splenocytes from nontumor-bearing control animals (no treatment, C44, and mch1N11 + anti-PD-1 treated), tumor-bearing animals (C44 treated), and mice resistance to E0771 rechallenge (Fig. 4a, 4b) were utilized. All analyses were performed in triplicate

Back to article page
\